- Home
- ABSI vs TRVI Comparison
ABSI vs TRVI Comparison
Compare ABSI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- TRVI
- Stock Information
- Founded
- ABSI 2011
- TRVI 2011
- Country
- ABSI United States
- TRVI United States
- Employees
- ABSI N/A
- TRVI N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- TRVI Health Care
- Exchange
- ABSI Nasdaq
- TRVI Nasdaq
- Market Cap
- ABSI 318.2M
- TRVI 341.4M
- IPO Year
- ABSI 2021
- TRVI 2019
- Fundamental
- Price
- ABSI $3.82
- TRVI $3.90
- Analyst Decision
- ABSI Strong Buy
- TRVI Strong Buy
- Analyst Count
- ABSI 7
- TRVI 8
- Target Price
- ABSI $8.57
- TRVI $9.31
- AVG Volume (30 Days)
- ABSI 7.4M
- TRVI 494.7K
- Earning Date
- ABSI 03-20-2025
- TRVI 03-19-2025
- Dividend Yield
- ABSI N/A
- TRVI N/A
- EPS Growth
- ABSI N/A
- TRVI N/A
- EPS
- ABSI N/A
- TRVI N/A
- Revenue
- ABSI $4,207,000.00
- TRVI N/A
- Revenue This Year
- ABSI $8.57
- TRVI N/A
- Revenue Next Year
- ABSI $169.72
- TRVI N/A
- P/E Ratio
- ABSI N/A
- TRVI N/A
- Revenue Growth
- ABSI N/A
- TRVI N/A
- 52 Week Low
- ABSI $2.45
- TRVI $1.35
- 52 Week High
- ABSI $6.72
- TRVI $4.68
- Technical
- Relative Strength Index (RSI)
- ABSI 58.87
- TRVI 51.51
- Support Level
- ABSI $3.53
- TRVI $3.47
- Resistance Level
- ABSI $4.04
- TRVI $4.07
- Average True Range (ATR)
- ABSI 0.36
- TRVI 0.26
- MACD
- ABSI 0.09
- TRVI -0.03
- Stochastic Oscillator
- ABSI 66.76
- TRVI 71.57
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.